Michael Tolentino Decoding The Human Immune System

Could a new generation of therapeutics change the standard of care for vision-threatening illnesses? In this episode, Dr. Michael Tolentino, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics, explores the groundbreaking potential of glycol therapeutics in transforming the treatment landscape for degenerative eye diseases. Drawing on decades of research and clinical insight, Dr. Tolentino explains how these novel therapies can change the way we look at eye conditions. He also delves into the mentors who shaped his scientific journey, offering insight into the pivotal relationships and experiences that guided his career while reflecting on how this path ultimately led him to co-found Aviceda Therapeutics and pioneer a new approach to treating vision-threatening diseases. Tune in to learn how this emerging field could redefine how we preserve and restore vision for millions.